Alpine Immune Sciences
Seattle, US · Founded 2014 · Delaware corporation · 29 employees on LinkedIn · 3 known investors
Founders & leadership
Alpine Immune Sciences was founded in 2014 by Dr. Mitchell H Gold and Mitchell Gold.
DM
Dr. Mitchell H GoldCo-founder
MG
Mitchell GoldExecutive Chairman and Chief Executive Officer
MK
Michael KornackerExecutive
RS
Ryan SwansonExecutive
DM
David MillerExecutive
JP
James Paul RickeySenior Vice President and Chief Financial Officer
MJ
Mark James LittonPresident and Chief Operating Officer
JV
Jay VenkatesanNamed on SEC filing
PT
Peter ThompsonNamed on SEC filing
CP
RC
Robert ConwayNamed on SEC filing
PS
Paul SekhriNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$234.9M disclosed across 7 rounds · 2014–2021
▶$91MraisedSep 2021 · 16 investors · BiotechnologyRule 506(b)
▶$91MraisedSep 2021 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stanford PengExecutive Officer
- Robert ConwayDirector
- Peter ThompsonDirector
- Jay VenkatesanDirector
- Zelanna GoldbergExecutive Officer
- Natasha HerndayDirector
- James Paul RickeyExecutive Officer
- Cui XiangminDirector
- Mitchell GoldExecutive Officer, Director
- James TopperDirector
- Christopher PeetzDirector
- Offering amount
- $91M
- Amount sold
- $91M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60MraisedAug 2020 · 25 investors · BiotechnologyRule 506(b)
▶$60MraisedAug 2020 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert ConwayDirector
- Paul SekhriDirector
- Cui XiangminDirector
- James TopperDirector
- Jay VenkatesanDirector
- James Paul RickeyExecutive Officer
- Peter ThompsonDirector
- Mitchell GoldExecutive Officer, Director
- Stanford PengExecutive Officer
- Christopher PeetzDirector
- Offering amount
- $82.7M
- Amount sold
- $60M
- Sales commissions
- $3.3M
- Placement agents
- Oppenheimer & Co. Inc., Cowen and Company
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.3MraisedJan 2019 · 8 investors · BiotechnologyRule 506(b)
▶$25.3MraisedJan 2019 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jay VenkatesanDirector
- James Paul RickeyExecutive Officer
- Mitchell GoldExecutive Officer, Director
- James TopperDirector
- Mark James LittonExecutive Officer
- Cui XiangminDirector
- Peter ThompsonDirector
- Christopher PeetzDirector
- Robert ConwayDirector
- Stanford PengExecutive Officer
- Paul SekhriDirector
- Offering amount
- $48.7M
- Amount sold
- $25.3M
- Sales commissions
- $907.5K
- Finders' fees
- $75K
- Placement agents
- Piper Jaffray & Co.
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17MraisedJul 2017 · 3 investors · BiotechnologyRule 506(b)
▶$17MraisedJul 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stanford PangExecutive Officer
- Peter ThompsonDirector
- Mitchell H. GoldExecutive Officer, Director
- Jay VenkatesanExecutive Officer, Director
- J. Paul RickeyExecutive Officer
- James TopperDirector
- Offering amount
- $17M
- Amount sold
- $17M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$10.3MraisedJun 2016 · 3 investors · BiotechnologyRule 506(b)
▶$10.3MraisedJun 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan SwansonExecutive Officer
- Peter ThompsonDirector
- Mitchell H. GoldExecutive Officer, Director
- Jay VenkatesanExecutive Officer, Director
- James TopperDirector
- David MillerExecutive Officer
- Michael KornackerExecutive Officer
- Offering amount
- $48M
- Amount sold
- $10.3M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1.3MraisedMay 2015 · 1 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMay 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dr. Mitchell H GoldExecutive Officer, Director
- Michael KornackerExecutive Officer, Director
- Ryan SwansonExecutive Officer, Director
- David MillerExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$30MraisedNov 2014 · 12 investors · PharmaceuticalsRule 506(b)
▶$30MraisedNov 2014 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan LeffDirector
- Tom SokolowskiExecutive Officer
- Howard FurstDirector
- Evan LohDirector
- John MooreDirector
- Joseph LoscalzoDirector
- Offering amount
- $40M
- Amount sold
- $30M
- Finders' fees
- $845.6K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Alpine Immune Sciences went on to found or lead other companies.
In the news
Frequently asked questions
- Who founded Alpine Immune Sciences?
- Alpine Immune Sciences was founded by Dr. Mitchell H Gold, Mitchell Gold in 2014.
- Who are Alpine Immune Sciences's investors?
- Alpine Immune Sciences's investors include Decheng Capital, Frazier Life Sciences, Biotechnology Value Fund.
- How much funding has Alpine Immune Sciences raised?
- Alpine Immune Sciences has disclosed $234.9M raised across 7 rounds.
- Where is Alpine Immune Sciences headquartered?
- Alpine Immune Sciences is headquartered in Seattle, US.